FGL1 facilitates rather than suppresses anticancer immunity against microsatellite instable gastric cancer

FGL1 facilitates rather than suppresses anticancer immunity against microsatellite instable gastric cancer

  • Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396:635–48.

    Article
    CAS
    PubMed

    Google Scholar

  • Wu Y, Hu G, Wu R, Gong N. High expression of miR-135b predicts malignant transformation and poor prognosis of gastric cancer. Life Sci. 2020;257:118133.

    Article
    CAS
    PubMed

    Google Scholar

  • Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71:264–79.

    Article
    PubMed
    PubMed Central

    Google Scholar

  • Vrana D, Matzenauer M, Neoral C, Aujesky R, Vrba R, Melichar B, et al. From tumor immunology to immunotherapy in gastric and esophageal cancer. Int J Mol Sci. 2018;20;13.

  • Ratti M, Lampis A, Hahne JC, Passalacqua R, Valeri N. Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches. Cell Mol Life Sci. 2018;75:4151–62.

    Article
    CAS
    PubMed
    PubMed Central

    Google Scholar

  • Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.

    Article

    Google Scholar

  • Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167–75.

    Article
    CAS
    PubMed
    PubMed Central

    Google Scholar

  • Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409–13.

    Article
    CAS
    PubMed
    PubMed Central

    Google Scholar

  • Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N. Engl J Med. 2015;372:2509–20.

    Article
    CAS
    PubMed
    PubMed Central

    Google Scholar

  • Carethers JM. High predictability for identifying Lynch syndrome via microsatellite instability testing or immunohistochemistry in all Lynch-associated tumor types. Transl cancer Res. 2019;8:S559–S563.

    Article
    PubMed
    PubMed Central

    Google Scholar

  • Li K, Zhang A, Li X, Zhang H, Zhao L. Advances in clinical immunotherapy for gastric cancer. Biochim Biophys Acta Rev Cancer. 2021;1876:188615.

    Article
    CAS
    PubMed

    Google Scholar

  • Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16:361–75.

    Article
    PubMed
    PubMed Central

    Google Scholar

  • Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5:43–51.

    Article
    CAS
    PubMed

    Google Scholar

  • Shi AP, Tang XY, Xiong YL, Zheng KF, Liu YJ, Shi XG, et al. Immune checkpoint LAG3 and its ligand FGL1 in cancer. Front Immunol. 2021;12:785091.

    Article
    CAS
    PubMed

    Google Scholar

  • Guo M, Yuan F, Qi F, Sun J, Rao Q, Zhao Z, et al. Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8(+)T cells in hepatocellular carcinoma using multiplex quantitative analysis. J Transl Med. 2020;18:306.

    Article
    CAS
    PubMed
    PubMed Central

    Google Scholar

  • Qian W, Zhao M, Wang R, Li H. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target. J Hematol Oncol. 2021;14:147.

    Article
    CAS
    PubMed
    PubMed Central

    Google Scholar

  • Wang J, Sanmamed MF, Datar I, Su TT, Ji L, Sun J, et al. Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. Cell. 2019;176:334–47e12.

    Article
    CAS
    PubMed

    Google Scholar

  • Tang XY, Xiong YL, Shi AP, Sun Y, Han Q, Lv Y, et al. The downregulation of fibrinogen-like protein 1 inhibits the proliferation of lung adenocarcinoma via regulating MYC-target genes. Transl Lung Cancer Res. 2022;11:404–19.

    Article
    CAS
    PubMed
    PubMed Central

    Google Scholar

  • Zhang Y, Qiao HX, Zhou YT, Hong L, Chen JH. Fibrinogen‑like‑protein 1 promotes the invasion and metastasis of gastric cancer and is associated with poor prognosis. Mol Med Rep. 2018;18:1465–72.

    CAS
    PubMed
    PubMed Central

    Google Scholar

  • Liu C, Liu R, Wang B, Lian J, Yao Y, Sun H, et al. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer. J Immunother Cancer. 2021;9;e001895.

  • Xu X, Lv J, Guo F, Li J, Jia Y, Jiang D, et al. Gut microbiome influences the efficacy of PD-1 antibody immunotherapy on MSS-type colorectal cancer via metabolic pathway. Front Microbiol. 2020;11:814.

    Article
    PubMed
    PubMed Central

    Google Scholar

  • Wu X, Tao P, Zhou Q, Li J, Yu Z, Wang X, et al. IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathway. Oncotarget. 2017;8:20741–50.

    Article
    PubMed
    PubMed Central

    Google Scholar

  • Ancey PB, Contat C, Boivin G, Sabatino S, Pascual J, Zangger N, et al. GLUT1 expression in tumor-associated neutrophils promotes lung cancer growth and resistance to radiotherapy. Cancer Res. 2021;81:2345–57.

    Article
    CAS
    PubMed
    PubMed Central

    Google Scholar

  • Gu S, Hou Y, Dovat K, Dovat S, Song C, Ge Z. Synergistic effect of HDAC inhibitor chidamide with cladribine on cell cycle arrest and apoptosis by targeting HDAC2/c-Myc/RCC1 axis in acute myeloid leukemia. Exp Hematol Oncol. 2023;12:23.

    Article
    CAS
    PubMed
    PubMed Central

    Google Scholar

  • Sun C, Gao W, Liu J, Cheng H, Hao J. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer. Respir Res. 2020;21:210.

    Article
    CAS
    PubMed
    PubMed Central

    Google Scholar

  • Kim S, Kim YJ, Chung WC. HER-2 positivity is a high risk of recurrence of stage I gastric cancer. Korean J Intern Med. 2021;36:1327–37.

    Article
    CAS
    PubMed
    PubMed Central

    Google Scholar

  • Gu H, Lin R, Zheng F, Zhang Q. ELK1 activated-long noncoding RNA LBX2-AS1 aggravates the progression of ovarian cancer through targeting miR-4784/KDM5C axis. J Mol Histol. 2021;52:31–44.

    Article
    CAS
    PubMed

    Google Scholar

  • Pietrantonio F, Miceli R, Raimondi A, Kim YW, Kang WK, Langley RE, et al. Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J Clin Oncol. 2019;37:3392–400.

    Article
    PubMed

    Google Scholar

  • Lv Z, Cui B, Huang X, Feng HY, Wang T, Wang HF, et al. FGL1 as a novel mediator and biomarker of malignant progression in clear cell renal cell carcinoma. Front Oncol. 2021;11:756843.

    Article
    CAS
    PubMed
    PubMed Central

    Google Scholar

  • Wang Y, Xia W, Shen F, Zhou J, Gu Y, Chen Y. tRNA-derived fragment tRF-Glu49 inhibits cell proliferation, migration and invasion in cervical cancer by targeting FGL1. Oncol Lett. 2022;24:334.

    Article
    CAS
    PubMed
    PubMed Central

    Google Scholar

  • Wan WJ, Huang G, Wang Y, Tang Y, Li H, Jia CH, et al. Coadministration of iRGD peptide with ROS-sensitive nanoparticles co-delivering siFGL1 and siPD-L1 enhanced tumor immunotherapy. Acta Biomater. 2021;136:473–84.

    Article
    CAS
    PubMed

    Google Scholar

  • Gao Y, Zhang Z, Du J, Yang X, Wang X, Wen K, et al. Xue-Jie-San restricts ferroptosis in Crohn’s disease via inhibiting FGL1/NF-kappaB/STAT3 positive feedback loop. Front Pharm. 2023;14:1148770.

    Article
    CAS

    Google Scholar

  • Pflug KM, Sitcheran R. Targeting NF-kappaB-inducing kinase (NIK) in immunity, inflammation, and cancer. Int J Mol Sci. 2020; 21;8470.

  • Song Y, Gu Y, Hu X, Wang M, He Q, Li Y. Endometrial tumors with MSI-H and dMMR share a similar tumor immune microenvironment. Onco Targets Ther. 2021;14:4485–97.

    Article
    PubMed
    PubMed Central

    Google Scholar

  • Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, et al. Durable clinical benefit with nivolumab plus ipilimumab in dna mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36:773–9.

    Article
    CAS
    PubMed

    Google Scholar

  • Eng C, Kim TW, Bendell J, Argiles G, Tebbutt NC, Di Bartolomeo M, et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019;20:849–61.

    Article
    CAS
    PubMed

    Google Scholar

  • Qian Y, Sun Y, Shi P, Zhou X, Zhang Q, Dong Q et al. Development of LAG-3/FGL1 blocking peptide and combination with radiotherapy for cancer immunotherapy. Acta Pharmaceutica Sinica B. 2023.

  • Zinn S, Vazquez-Lombardi R, Zimmermann C, Sapra P, Jermutus L, Christ D. Advances in antibody-based therapy in oncology. Nat Cancer. 2023;4:165–80.

    Article
    PubMed

    Google Scholar

  • Leave a Reply

    Your email address will not be published. Required fields are marked *